Table 3.

Immunohistochemical expression of cyclin E2 and Ki67 in CD3-positive tumor population of TNKLPD

Case No.	Diagnosis	Ohshima category	Histology	Cyclin E2 (%)	Ki67 (%)	Follow up	OS (mth)
1	CAEBV	A1	P	3	5	Alive	55
2	CAEBV	A1	P	8	NA	Dead (AHCT complications)	48
3	CAEBV	A1	P	0	0	Alive	6
4	STLPDC	A2	P	8	6	Alive	64
5	STLPDC	A2	P	1	1	Alive cgraft rejection)	95
6	STLPDC	A2	P	5	12	Alive	31
7	STLPDC	A2	P	8	3	Dead	14
8	CAEBV vs STLPDC	A1 or A2	P	8	1	Alive	94.4
9	CAEBV vs STLPDC	A1 or A2	P	7	8	Alive	9.2
10	CAEBV vs STLPDC	A1 or A2	P	8	9	Alive	32.5
11	CAEBV vs STLPDC	A1 or A2	P	44	4	Dead	21.8
12	STLPDC	A3	M	90	NA	Dead	0.4
13	STLPDC	A3	M	70	75	Alive	21
14	STLPDC	B	M	49	44	Dead	0.83
15	STLPDC	B	M	35	NA	Dead	2
16	STLPDC	B	M	70	70	Dead	1
17	STLPDC	B	M	15	60	Dead	1.16
18	STLPDC	B	M	30	82	NA	NA
19	STLPDC	B	M	35	90	Dead	1
20	STLPDC	B	M	18	23	Dead	0.1
21	STLPDC	B	M	65	52	Dead	2.2
22	favour STLPDC	A3 or B	M	NA	NA	Dead	0.7

Abbreviations: NA not available, mth months, P polymorphic, M monomorphic.